Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study

Psoriasis

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Br J Dermatol

Iskandar IYK, Lunt M, Thorneloe RJ, Cordingley L, Griffiths CEM, Ashcroft DM, British Association of Dermatologists Biologics, Immunomodulators Register, Psoriasis Stratification to Optimise Relevant Therapy Study Groups.

doi: 10.1111/bjd.20577

Psoriasis

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol.

Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group.

doi: 10.1111/bjd.18981.

Acne

Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study

Br J Dermatol.

Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peris K

doi: 10.1111/bjd.18983.

Psoriasis

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

J Am Acad Dermatol.

Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guérin A, Singh R, Ganguli A

doi: 10.1016/

Psoriasis

Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: Results from a prospective, randomized, observer-blinded head-to-head trial

J Eur Acad Dermatol Venereol.

Holzer G, Hoke M, Sabeti-Sandor S, Perkmann T, Rauscher A, Strassegger B, Radakovic S, Tanew A

doi: 10.1111/jdv.16635.

COMMENTED

Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study

J Rheumatol.

Zufferey P, Scherer A, Nissen MJ, Ciurea A, Tamborrini G, Brulhart L, Blumhardt S, Toniolo M, Möller B, Ziswiler HR; SONAR Group and the SCQM Foundation

doi: 10.3899/jrheum.161193.

Psoriasis

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

J Eur Acad Dermatol Venereol.

Piaserico S, Dapavo P, Conti A, Gisondi P, Russo FP

doi: 10.1111/jdv.14146.

Psoriatic Arthritis

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab

Rheumatology (Oxford).

Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Gnann H, Greger G, Tony HP, Burkhardt H

doi: 10.1093/

Psoriasis

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group

J Eur Acad Dermatol Venereol.

Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barri S, Muñoz C, Llamas M, Valentí F, Josune Mitxelena M, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Manuel Carrascosa J

doi: 10.1111/jdv.16439.

Related content

Alcohol abuse associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study

Drug Survival of Adalimumab, Ustekinumab, and Secukinumab in Patients with Psoriasis: a Prospective Cohort Study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-α inhibitors versus phototherapy: An observational cohort study

Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: Results from a prospective, randomized, observer-blinded head-to-head trial

Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab

Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis Group